An Open Label, Prospective, Observational, Local, Non-interventional Study of BeVacizumab (Avastin) and IntErpherone (IFN) Alpha 2a in Patients With Metastatic and Locally Advanced Renal Cell CAncer (VERA Study).

Trial Profile

An Open Label, Prospective, Observational, Local, Non-interventional Study of BeVacizumab (Avastin) and IntErpherone (IFN) Alpha 2a in Patients With Metastatic and Locally Advanced Renal Cell CAncer (VERA Study).

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Jul 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Interferon alpha-2a (Primary)
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Acronyms VERA
  • Sponsors Roche
  • Most Recent Events

    • 31 Jul 2015 Status changed from active, no longer recruiting to completed as reported in ClinicalTrial.gov.
    • 19 Nov 2014 Planned End Date changed from 1 Oct 2014 to 1 Jun 2015 as reported in ClinicalTrial.gov.
    • 19 Nov 2014 Planned primary completion date changed from 1 Oct 2014 to 1 Jun 2015 as reported in ClinicalTrial.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top